SG10201604468QA - Shk-based pharmaceutical compositions and methods of manufacturing and using the same - Google Patents

Shk-based pharmaceutical compositions and methods of manufacturing and using the same

Info

Publication number
SG10201604468QA
SG10201604468QA SG10201604468QA SG10201604468QA SG10201604468QA SG 10201604468Q A SG10201604468Q A SG 10201604468QA SG 10201604468Q A SG10201604468Q A SG 10201604468QA SG 10201604468Q A SG10201604468Q A SG 10201604468QA SG 10201604468Q A SG10201604468Q A SG 10201604468QA
Authority
SG
Singapore
Prior art keywords
shk
manufacturing
methods
same
pharmaceutical compositions
Prior art date
Application number
SG10201604468QA
Other languages
English (en)
Inventor
Shawn P Iadonato
Eric J Tarcha
Original Assignee
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta One Llc filed Critical Kineta One Llc
Publication of SG10201604468QA publication Critical patent/SG10201604468QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/12—Gas jars or cylinders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
SG10201604468QA 2011-06-06 2012-06-05 Shk-based pharmaceutical compositions and methods of manufacturing and using the same SG10201604468QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493868P 2011-06-06 2011-06-06
US201261625578P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
SG10201604468QA true SG10201604468QA (en) 2016-07-28

Family

ID=47296695

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201604468QA SG10201604468QA (en) 2011-06-06 2012-06-05 Shk-based pharmaceutical compositions and methods of manufacturing and using the same
SG2013089842A SG195302A1 (en) 2011-06-06 2012-06-05 Shk-based pharmaceutical compositions and methods of manufacturing and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013089842A SG195302A1 (en) 2011-06-06 2012-06-05 Shk-based pharmaceutical compositions and methods of manufacturing and using the same

Country Status (13)

Country Link
US (3) US9381261B2 (https=)
EP (2) EP3263123A3 (https=)
JP (2) JP6250536B2 (https=)
KR (1) KR20140038501A (https=)
CN (1) CN103687608B (https=)
AU (2) AU2012268441B2 (https=)
BR (1) BR112013031370A2 (https=)
CA (1) CA2838474A1 (https=)
MX (1) MX351353B (https=)
RU (1) RU2637085C2 (https=)
SG (2) SG10201604468QA (https=)
TW (2) TW201542231A (https=)
WO (1) WO2012170392A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170392A2 (en) 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
EP3024472A4 (en) * 2013-07-22 2017-06-28 Kineta One, LLC Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
JP6847828B2 (ja) * 2014-08-15 2021-03-24 モナッシュ ユニバーシティ 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
LT3288379T (lt) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
KR102533290B1 (ko) * 2022-04-14 2023-05-16 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드
KR102553070B1 (ko) * 2022-06-16 2023-07-07 한국해양과학기술원 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드
WO2026003546A1 (en) 2024-06-27 2026-01-02 Vrg Miniprotein Zrt Potassium ion kv1.3 channel inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
AU7093396A (en) * 1995-09-07 1997-03-27 Elan Medical Technologies Limited Medicament conversion system
WO1998023639A2 (en) * 1996-11-27 1998-06-04 University Of Florida ShK TOXIN COMPOSITIONS AND METHODS OF USE
WO1999013895A1 (en) 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
EP0953576B1 (en) * 1998-04-30 2005-11-02 Curis, Inc. Active hedgehog protein conjugate, process for its production and use
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1904130B1 (en) 2005-06-21 2016-03-30 Eli Lilly And Company Needled pharmaceutical delivery device with triggered automatic needle insertion and manually controlled pharmaceutical injection
US20110163469A1 (en) 2005-12-16 2011-07-07 Massachusetts Institute Of Technology High-throughput fabrication of microparticles
WO2009021289A1 (en) 2007-08-14 2009-02-19 The Walter And Eliza Hall Institute Of Medical Research Potassium channel inhibitors
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
EP2408814B1 (en) * 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012170392A2 (en) 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
IN2014CN03333A (https=) * 2011-10-03 2015-07-03 Univ California
US20160338967A1 (en) * 2013-12-23 2016-11-24 Kineta One, Llc Sustained release depot formulations of therapeutic proteins, and uses thereof

Also Published As

Publication number Publication date
US9878058B2 (en) 2018-01-30
CN103687608B (zh) 2018-06-26
RU2637085C2 (ru) 2017-11-29
EP3263123A2 (en) 2018-01-03
US20140221271A1 (en) 2014-08-07
WO2012170392A3 (en) 2013-03-14
JP2014517005A (ja) 2014-07-17
US9381261B2 (en) 2016-07-05
JP2018008955A (ja) 2018-01-18
KR20140038501A (ko) 2014-03-28
AU2016208422A1 (en) 2016-08-18
AU2012268441B2 (en) 2016-05-12
JP6250536B2 (ja) 2017-12-20
EP2717899A2 (en) 2014-04-16
US20160045627A1 (en) 2016-02-18
CN103687608A (zh) 2014-03-26
TWI535455B (zh) 2016-06-01
RU2013157823A (ru) 2015-07-20
MX2013014401A (es) 2014-09-25
MX351353B (es) 2017-10-11
EP2717899A4 (en) 2015-07-29
US20160331847A1 (en) 2016-11-17
BR112013031370A2 (pt) 2016-11-29
SG195302A1 (en) 2013-12-30
EP3263123A3 (en) 2018-05-16
TW201300133A (zh) 2013-01-01
TW201542231A (zh) 2015-11-16
CA2838474A1 (en) 2012-12-13
AU2012268441A1 (en) 2013-12-19
WO2012170392A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
GB2507210B (en) Insecticidal compositions and methods of using the same
ZA201309060B (en) Synthetic formulations and methods of manufacturing and using thereof
ZA201402734B (en) Collector compositions and methods of using the same
IL228322A0 (en) History of dispiropyrrolidine, preparations containing them and their uses
IL252566B (en) Pharmacy preparations and methods
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
ZA201208265B (en) Pharmaceutical compositions and methods of making same
IL230650A (en) Methylphenidate-drug-mediators and processes for their preparation and use
LT3378862T (lt) Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui
SG10201603027QA (en) Antimicrobial compounds and methods of making and using the same
IL227538B (en) Topical minocycline preparations and methods of using them
SG11201403215TA (en) Cyclic compounds and methods of making and using the same
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
ZA201308892B (en) Compositions and methods
EP2665480A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM
ZA201407978B (en) Compositions and methods for the alteration of xlhed phenotypes
GB201208315D0 (en) Pharmaceutical methods and compositions
IL231490A0 (en) Preparations and methods for the production and use of human cholinesterases
HK1196259A (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
GB201110598D0 (en) Pharmaceutical compositions and devices
AU2011900931A0 (en) Pharmaceutical compositions and use thereof
AU2011903938A0 (en) Therapeutic methods and compositions